Inhaled heparin in pneumonia

Study of the effect of inhaled heparin on duration of antibiotic therapy in patients with ventilator associated pneumonia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140310016917N8

Enrollment

Registered

2019-07-11

Start date

2019-06-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VENTILATOR ASSOCIATED PNEUMONIA(VAP). Ventilator associated pneumonia

Interventions

Intervention 1: Intervention group: after appropriate randomization drug (nebulized heparin in this group) in dose of 2 cc (10,000 heparin units) every 4 hours is given through a jet nebulizer loca

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients are included in the study according to the score of the severity of pulmonary infection index (>=6) and age above 18 years old.

Exclusion criteria

Exclusion criteria: Mechanical ventilation less than 48 h during hospitalization Cancer and immunedeficient patients chronic infection and coinfection in other sites of body Do not resuscisate patients CRRT dependency Theraputic dose of any anticoagulants BMI>40 History of allergy to heparin and HIT History of bleeding in 3 month ago and bleeding tendency ICH in 1year ago possibility of epidural catheter insertion during next 48 h

Design outcomes

Primary

Measure	Time frame
Duration of antibiotic therapy. Timepoint: Every other day, procalcitonin is measured to determine the length of antibiotic treatment. Method of measurement: Procalcitonin Measuring Kit.	—

Secondary

Measure	Time frame
Clinical pulmonary infection severity score. Timepoint: On admission and daily. Method of measurement: Clinical Information Collection Form.;C Reactive Protein. Timepoint: On admission then daily. Method of measurement: Clinical Information Collection Form.;Sepsis Organ Failure Assessment score. Timepoint: On admission then daily. Method of measurement: Clinical Information Collection Form.;Acute Physiologic And Chronic Health Evaluation II score. Timepoint: on addmision then daily. Method of measurement: Clinical Information Collection Form.	—

Measure

Time frame

Clinical pulmonary infection severity score. Timepoint: On admission and daily. Method of measurement: Clinical Information Collection Form.;C Reactive Protein. Timepoint: On admission then daily. Method of measurement: Clinical Information Collection Form.;Sepsis Organ Failure Assessment score. Timepoint: On admission then daily. Method of measurement: Clinical Information Collection Form.;Acute Physiologic And Chronic Health Evaluation II score. Timepoint: on addmision then daily. Method of measurement: Clinical Information Collection Form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Saeedinia

Guilan University of Medical Sciences

mostafa.saeedinia@gmail.com+98 13 1321 0434

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026